Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease.
about
Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organsBuruli ulcer (M. ulcerans infection): new insights, new hope for disease control.Analysis of the vaccine potential of plasmid DNA encoding nine mycolactone polyketide synthase domains in Mycobacterium ulcerans infected miceImproved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boostingCytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana.Family relationship, water contact and occurrence of Buruli ulcer in Benin.Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice.Buruli ulcer.Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis.Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.Cytokine mRNA expression in Mycobacterium ulcerans-infected human skin and correlation with local inflammatory response.Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad modelEvidence for an intramacrophage growth phase of Mycobacterium ulcerans.Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer.Interferon-γ Is a Crucial Activator of Early Host Immune Defense against Mycobacterium ulcerans Infection in Mice.Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infectionSelective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone.Analysis of Mycobacterium ulcerans-specific T-cell cytokines for diagnosis of Buruli ulcer disease and as potential indicator for disease progression.Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humansMycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria.Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.History, biology and chemistry of Mycobacterium ulcerans infections (Buruli ulcer disease).Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease.Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans.Systemic and local interferon-gamma production following Mycobacterium ulcerans infection.Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin.Susceptibility to Mycobacterium ulcerans Disease (Buruli ulcer) Is Associated with IFNG and iNOS Gene Polymorphisms.The local immune response in ulcerative lesions of Buruli disease.Differences in virulence and immune response induced in a murine model by isolates of Mycobacterium ulcerans from different geographic areas.Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases.Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans
P2860
Q21090122-F8933C13-060C-4EA1-ACAA-8FA2C7403A04Q21144731-C09D96C3-C96A-4051-BB9A-F01E29BF89FFQ28538249-7A0CB20F-3709-4A8D-BEBA-B9E6C7819C0CQ33324374-9235BA59-E957-419F-8CA6-0031FEB1171CQ33593952-27596C7B-9EFA-44D6-8D48-6F026A2AF55BQ33991576-0E3F197E-1294-4444-A94F-E302B5DFA2B9Q34033119-727BA1A9-563E-44A2-AB07-14B7C24BAC54Q34229628-EC0B0A58-8CEA-4236-8639-BEF4E809787BQ34429309-16EAC4F2-E58C-48BD-8647-EF23C2E1312DQ34484489-CE184019-121B-4786-980B-16CC474D89E8Q34602038-78CB67FC-F303-472C-BE08-A1326ACD8FB9Q34702499-6A4F9C34-43AA-4DA4-B19B-936CE986116AQ35689228-4CB9909F-C559-4352-8EE3-DB30AFA71B9BQ35782951-38DA34CA-93E7-4264-A081-1DC45EFC6E90Q35919532-3B519FC8-0E0D-4EFA-BF36-476726FE9624Q35949741-C11C479C-660B-43C7-96F0-1053FC158066Q36229394-2F85EB2D-D1C2-4E1C-BFE3-C92819FF24AAQ36291527-2647FABB-82F3-48CD-B9EC-50E93ED0ED57Q37051036-40ED0607-891E-48C3-A6A4-25E966127F88Q37170768-9FD170A8-DAC3-46AE-8DD4-6000170E2409Q37349850-2867F3F2-ADB7-4D08-99F2-CE250BB95252Q38157768-9CDE2539-4A8C-4920-910A-19EBA1F6B116Q38634493-672C2AE0-8E8E-4936-B005-01B0D1E14970Q38972659-98247622-EF2F-4561-A5B8-A455FB780940Q39436449-51568B19-16A9-45E6-AC69-D4DFB7F05FC1Q40399156-6CDF8D52-8445-43BE-A118-1AF7EA5EA9F3Q42372966-FEA2C905-6163-42BE-9A6C-B4EFB4EB161BQ44814557-D1846D00-1A62-4A1A-A127-307432944890Q45928623-6439CB97-52BD-40E8-A90A-C9993D3DEEC5Q48176377-43BD48B0-DDC8-4E80-80D5-1C57E4315222Q57203196-F4982F6A-51FC-43E4-80F9-727405AC6AEC
P2860
Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Differential production of sys ...... ative forms of Buruli disease.
@ast
Differential production of sys ...... ative forms of Buruli disease.
@en
type
label
Differential production of sys ...... ative forms of Buruli disease.
@ast
Differential production of sys ...... ative forms of Buruli disease.
@en
prefLabel
Differential production of sys ...... ative forms of Buruli disease.
@ast
Differential production of sys ...... ative forms of Buruli disease.
@en
P2093
P2860
P50
P1476
Differential production of sys ...... ative forms of Buruli disease.
@en
P2093
Audrey Tanghe
Eliane Bourreau
Pascal Launois
Roger Pradinaud
P2860
P304
P356
10.1128/IAI.72.2.958-965.2004
P407
P577
2004-02-01T00:00:00Z